Physicians' Academy for Cardiovascular Education

siRNA therapy and LDL-C

Follow news on the evolving field of siRNA therapy and lowerting of LDL-c

Targeting the PCSK9 pathway: where do novel therapies fit in?

10' education - Oct. 5, 2022 - Ann Marie Navar, MD, PhD

Changing paradigms in LDL-c reduction

10' education - Sep. 28, 2022 - Prof. Kausik Ray, MD

Beginning of an era: Treatment of elevated Lp(a)

3' education - Apr. 6, 2022 - Steven Nissen, MD

Expanding therapeutic options for LDL-c lowering

10' education - Oct. 1, 2021 - Prof. Christie Ballantyne, MD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

The gap between guideline LDL-c goals and current practice: How are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

LDL-c still reduced after 1 year with siRNA against PCSK9

3' education - Aug. 28, 2017

LDL lowering for CVD prevention: From hypothesis to axiom

10' education - Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

A decade of innovation, guidelines, and paradigm shifts in LDL-c management

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

The goal of LDL-c management is to reduce long-term CVD risk. Statins form the foundation of lipid-lowering therapy, but more ammunition is needed to attain LDL-c goals in all patients. This series of 3 presentations discusses current and evolving therapeutic LDL-c lowering options.

Efficacy and safety of PCSK9 siRNA in primary prevention cohort

Literature - Nov. 23, 2022 - Ray KK, et al. - Eur Heart J. 2022

In an ORION-11 substudy, inclisiran reduced LDL-c, non-HDL-c and apoB levels in a subgroup of high-risk patients with elevated LDL-c but without prior CV events receiving maximally tolerated statin therapy.

Potential CV benefits of PCSK9 siRNA in high-risk patients with elevated LDL-c

Literature - Nov. 15, 2022 - Ray KK, et al. - Eur Heart J. 2022

A pooled analysis of ORION-9, -10 and -11 offers early insights into the potential of inclisiran to lower CV risk in high-risk patients with elevated LDL-c levels, while results of dedicated CV outcomes trials are awaited.

Sustained LDL-c lowering with PCSK9 siRNA up to 4 years

News - Nov. 10, 2022

AHA 2022 High CV risk patients in ORION-1 were invited to participate in open-label extension study with inclisiran -the ORION-3 study. What is the 4-year long-term efficacy and safety of inclisiran in these patients?

siRNA therapy reduces Lp(a) in patients with established ASCVD

News - Nov. 9, 2022

AHA 2022 The phase 2 OCEAN(a)-DOSE study showed that olpasiran dosed 75 mg or higher every 12 weeks reduces Lp(a) by >95% in patients with elevated Lp(a) and established ASCVD.

Expert consensus decision pathway on nonstatin therapies for LDL-c lowering

News - Oct. 10, 2022

The Journal of the American College of Cardiology has published the 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

Targeting the PCSK9 pathway: where do novel therapies fit in?

10' education - Oct. 5, 2022 - Ann Marie Navar, MD, PhD
Where do novel therapies targeting the PCSK9 pathway might fit in with regard to the lipid management paradigm? Ann Marie Navar gives an overview on current and future therapies.

Where do novel therapies targeting the PCSK9 pathway might fit in with regard to the lipid management paradigm? Ann Marie Navar gives an overview on current and future therapies.

Changing paradigms in LDL-c reduction

10' education - Sep. 28, 2022 - Prof. Kausik Ray, MD
Prof. Ray explains why therapy for LDL-c lowering in very high-risk patients should become like BP-combination therapy.

Prof. Ray explains why therapy for LDL-c lowering in very high-risk patients should become like BP-combination therapy.

Network meta-analysis of LLTs in patients with hypercholesterolemia and high CV risk

Literature - July 28, 2022 - Burnett H, et al. - Curr Med Res Opin. 2022

There have been no direct comparative studies of inclisiran, evolocumab, alirocumab, bempedoic acid, and ezetimibe in patients with hypercholesterolemia and increased cardiovascular risk receiving maximal tolerated statin therapy. A network meta-analysis may provide further insight.

Sustained LDL-c lowering with PCSK9 siRNA in patients with prior MI

News - Apr. 19, 2022

ACC 2022 A post hoc pooled analysis from the ORION-10 and ORION-11 trials showed that inclisiran, compared with placebo, in addition to statin and/or ezetimibe provided effective and sustained LDL-c lowering in patients with prior MI.

Beginning of an era: Treatment of elevated Lp(a)

3' education - Apr. 6, 2022 - Steven Nissen, MD
A phase 1 study showed that a siRNA targeting LPA mRNA reduced Lp(a) up to 98%. “It is an early study, this has got a long way to go, but we are optimistic that we are beginning an era where we going to be able to treat this disorder”, Nissen said.

ACC 2022 A phase 1 study showed that a siRNA targeting LPA mRNA reduced Lp(a) up to 98%. “It is an early study, this has got a long way to go, but we are optimistic that we are beginning an era where we are going to be able to treat this disorder”, Nissen said.

siRNA targeting LPA mRNA lowers Lp(a) levels

News - Apr. 3, 2022

ACC 2022 A phase 1 single ascending dose study showed that subcutaneous injection of SLN360, an siRNA targeting mRNA for the LPA gene, lowered Lp(a) up to 98% in adults with elevated Lp(a) levels.